6 July 2022 - NICE has issued fvidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

Setmelanotide is recommended, within its marketing authorisation, as an option for treating obesity and controlling hunger caused by pro-opiomelanocortin deficiency, including proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency in people 6 years and over. 

Read NICE highly specialised technologies guidance for setmelanotide